Apollo Hospitals Brings Next-Generation Lysin Science to India's Fight Against AMR - Collaborates with Precisio Biotix
Apollo Hospitals has partnered with Precisio Biotix to develop and clinically validate lysin-based antimicrobials in India. This collaboration aims to address antimicrobial resistance (AMR) by using enzyme-based therapies that target specific pathogens without the resistance issues associated with traditional antibiotics.
Why it matters
As AMR becomes a global health crisis, this partnership represents a significant shift toward precision medicine in treating drug-resistant infections.
HYDERABAD, India , July 21, 2026 /PRNewswire/ -- Apollo Hospitals today announced a strategic collaboration with Precisio Biotix to accelerate the development and clinical adoption of lysin-based antimicrobials in India - marking a significant step forward in combating antimicrobial resistance (AMR). This partnership will focus on translational research, clinical validation, and potential deployment pathways for lysin-based therapies across Apollo's network, with a focus on infectious diseases where existing treatment options are limited.
Lysins represent a next-generation class of precision antimicrobials - cell wall hydrolase enzymes that act rapidly, disrupt biofilms, and selectively target pathogens without contributing to antimicrobial resistance. Unlike conventional antibiotics, lysins offer a distinct mechanism to address high-burden, drug-resistant infections, including those associated with chronic and hospital-acquired conditions.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in